Qvar RediHaler
PHARMACY

Teva launches Qvar RediHaler

BY David Salazar

Teva has introduced its Qvar RediHaler, a breath-actuated aerosol inhaled corticosteroid that the company said is the first of its kind. The product, which Teva said eliminates the need for hand-breath coordination, is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients ages four years and older.

“Qvar has been an available asthma treatment option for well over a decade, so we are excited by the new technology of Qvar RediHaler that directly addresses an unmet need in the field of asthma management,” Teva executive vice president of North American commercial Brendan O’Grady said. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of Qvar RediHaler in the coming months.”

The product, which the Food and Drug Administration approved in August 2017, will replace the now-discontinued QVAR. Teva said Qvar RediHaler is designed to be ready to use without priming or shaking and without a spacer or volume-holding chamber. The company said that if desired, the new product will be priced at parity to Qvar.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
Camber's generic Viread
PHARMACY

Camber’s generic Viread launches

BY David Salazar

Camber Pharmaceuticals has launched its generic Viread (tenofovir disoproxil fumarate) tablets. The drug is indicated to treat Hepatitis B and HIV infection.

Camber’s generic Viread will be available in 30-count tablets of 300-mg dosage strength tablets. The product had U.S. sales of roughly $725 million for the 12 months ended November 2017, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
fda-approval-letter
PHARMACY

Sandoz launches new dosage strength of its Copaxone generic

BY David Salazar

Sandoz is launching its Glatopa, a generic of Copaxone (glatiramer acetate injection) following approval from the Food and Drug Administration on Tuesday. Glatopa was approved as a fully substitutable Copaxone generic in 40 mg/ml dosage strength. Sandoz launched Glatopa in 20 mg/ml dosage strength in 2015.

The Copaxone generic is indicated to treat relapsing forms of multiple sclerosis, and Sandoz developed Glatopa through a collaboration agreement between itself and Momenta Pharmaceuticals.

“The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products,” Sandoz CEO Richard Francis said. “We look forward to bringing this product to patients and healthcare professionals and providing a full range of patient support services for Glatopa through GlatopaCare.”

Sandoz’s GlatopaCare program offers a $0 co-pay support program for certain patients. The company also offers personalized injection training for patients, as well as a starter kit that includes the Glatopaject injection device that works with Glatopa prefilled syringes, Sandoz said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?